Literature DB >> 23988576

Prognostic factors and long-term outcome of pancreatic neuroendocrine neoplasms: Ki-67 index shows a greater impact on survival than disease stage. The large experience of the Spanish National Tumor Registry (RGETNE).

Elena Martin-Perez1, Jaume Capdevila, Daniel Castellano, Paula Jimenez-Fonseca, Ramon Salazar, Adolfo Beguiristain-Gomez, Vicente Alonso-Orduña, Purificacion Martinez Del Prado, Carles Villabona-Artero, Jose A Diaz-Perez, Antonio Monleon, Monica Marazuela, Vanessa Pachon, Javier Sastre-Valera, Isabel Sevilla, Angel Castaño, Rocio Garcia-Carbonero.   

Abstract

INTRODUCTION: Pancreatic neuroendocrine neoplasms (PNENs) are uncommon neoplasms with a wide spectrum of clinical behavior. The objective of this study was to assess in a large cohort of patients the relative impact of prognostic factors on survival.
METHODS: From June 2001 through October 2010, 1,271 patients were prospectively registered online (www.getne.org) at the Spanish National Cancer Registry for Gastroenteropancreatic Neuroendocrine Tumors (RGETNE) by participating centers. Clinical and histopathological features were assessed as potential prognostic factors by uni- and multivariate analyses.
RESULTS: Of 483 PNENs, 171 (35%) were functional (F) and 312 (65%) non-functional (NF). NF-PNENs were associated with a higher incidence of histological features denoting more aggressive disease, such as poor tumor differentiation, Ki-67 >20%, or vascular invasion (NF- vs. F-PNENs, respectively, p < 0.05). Nevertheless, functionality was not a significant predictor of survival (p = 0.19). Stage at diagnosis, Ki-67 index, tumor differentiation and surgical resection of the primary tumor were all significant prognostic factors in univariate analysis. However, Ki-67 (>20 vs. ≤2%) (hazard ratio (HR) 2.21, p = 0.01) and surgical resection (yes vs. no) (HR 0.92, p = 0.001) were the only independent predictors of survival in multivariate analysis. Among patients who underwent surgery, high Ki-67 index (HR 10.37, p = 0.02) and poor differentiation (HR 8.16, p = 0.03) were the only independent predictors of clinical outcome.
CONCLUSION: Ki-67 index and tumor differentiation are key prognostic factors influencing survival of patients with PNENs and, in contrast to what it is observed for other solid malignancies, they seem to have a greater impact on survival than the extent of disease. This should be borne in mind by physicians in order to appropriately tailor therapeutic strategies and surveillance of these patients.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23988576     DOI: 10.1159/000355152

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  20 in total

1.  Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.

Authors:  Lingaku Lee; Hisato Igarashi; Nao Fujimori; Masayuki Hijioka; Ken Kawabe; Yoshinao Oda; Robert T Jensen; Tetsuhide Ito
Journal:  Jpn J Clin Oncol       Date:  2015-09-15       Impact factor: 3.019

2.  Correlation of Ki-67 indices from biopsy and resection specimens of neuroendocrine tumours.

Authors:  J Barnes; S J Johnson; J J French
Journal:  Ann R Coll Surg Engl       Date:  2016-08-04       Impact factor: 1.891

3.  Histologic and molecular features of small well-differentiated pancreatic neuroendocrine tumors associated with the development of liver metastases.

Authors:  Paula Jiménez-Fonseca; Patricia Morales Del Burgo; Felipe Alvarez-Manceñido
Journal:  Hepatobiliary Surg Nutr       Date:  2019-08       Impact factor: 7.293

4.  A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients.

Authors:  Mohammad Y Zaidi; Alexandra G Lopez-Aguiar; Jeffrey M Switchenko; Joseph Lipscomb; Valentina Andreasi; Stefano Partelli; Adriana C Gamboa; Rachel M Lee; George A Poultsides; Mary Dillhoff; Flavio G Rocha; Kamran Idrees; Clifford S Cho; Sharon M Weber; Ryan C Fields; Charles A Staley; Massimo Falconi; Shishir K Maithel
Journal:  Ann Surg       Date:  2019-09       Impact factor: 12.969

5.  Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.

Authors:  Maurice Herring; Lynn Huynh; Mei Sheng Duh; Francis Vekeman; Audrey Tiew; Maureen Neary; Emily Bergsland
Journal:  Med Oncol       Date:  2017-04-09       Impact factor: 3.064

Review 6.  Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

7.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

8.  The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.

Authors:  Sule Ozturk Sari; Orhun Cig Taskin; Gokcen Gundogdu; Gulcin Yegen; Semen Onder; Metin Keskin; Sezer Saglam; Yasemin Ozluk; Mine Gulluoglu; Ozgur Mete
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

9.  Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE).

Authors:  Barbara Nuñez-Valdovinos; Alberto Carmona-Bayonas; Paula Jimenez-Fonseca; Jaume Capdevila; Ángel Castaño-Pascual; Marta Benavent; Jose Javier Pi Barrio; Alex Teule; Vicente Alonso; Ana Custodio; Monica Marazuela; Ángel Segura; Adolfo Beguiristain; Marta Llanos; Maria Purificacion Martinez Del Prado; Jose Angel Diaz-Perez; Daniel Castellano; Isabel Sevilla; Carlos Lopez; Teresa Alonso; Rocio Garcia-Carbonero
Journal:  Oncologist       Date:  2018-01-12

10.  Ki-67 Proliferation Index Assessment in Gastroenteropancreatic Neuroendocrine Tumors by Digital Image Analysis With Stringent Case and Hotspot Level Concordance Requirements.

Authors:  Sarag A Boukhar; Matthew D Gosse; Andrew M Bellizzi; Anand Rajan K D
Journal:  Am J Clin Pathol       Date:  2021-09-08       Impact factor: 2.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.